MX2011011772A - Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. - Google Patents

Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.

Info

Publication number
MX2011011772A
MX2011011772A MX2011011772A MX2011011772A MX2011011772A MX 2011011772 A MX2011011772 A MX 2011011772A MX 2011011772 A MX2011011772 A MX 2011011772A MX 2011011772 A MX2011011772 A MX 2011011772A MX 2011011772 A MX2011011772 A MX 2011011772A
Authority
MX
Mexico
Prior art keywords
tnf
alpha
human anti
antibodies
protein concentration
Prior art date
Application number
MX2011011772A
Other languages
English (en)
Inventor
Michael Neusius
Wolfgang Fraunhofer
Hans-Juergen Krause
Original Assignee
Abbott Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd
Publication of MX2011011772A publication Critical patent/MX2011011772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Abstract

La presente invención proporciona una formulación farmacéutica líquida que no incluye NaCI y que comprende más de 20 mg de un poliol y al menos aproximadamente 100 mg/mL de un anticuerpo humano anti-TNF-alfa o parte de enlace de antígeno del mismo. La presente invención proporciona una alta concentración de formulación de anticuerpo que tiene estabilidad a largo plazo, y características convenientes para administración subcutánea.
MX2011011772A 2009-05-04 2010-05-03 Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. MX2011011772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17538009P 2009-05-04 2009-05-04
PCT/US2010/033387 WO2010129469A1 (en) 2009-05-04 2010-05-03 Stable high protein concentration formulations of human anti-tnf-alpha-antibodies

Publications (1)

Publication Number Publication Date
MX2011011772A true MX2011011772A (es) 2012-02-08

Family

ID=43030509

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011772A MX2011011772A (es) 2009-05-04 2010-05-03 Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.

Country Status (16)

Country Link
US (3) US20100278822A1 (es)
EP (1) EP2427211A4 (es)
JP (1) JP2012526121A (es)
KR (1) KR20120038406A (es)
CN (2) CN102458469B (es)
AR (1) AR076748A1 (es)
AU (1) AU2010246168A1 (es)
CA (1) CA2760185A1 (es)
IL (1) IL215643A0 (es)
MX (1) MX2011011772A (es)
NZ (2) NZ595694A (es)
RU (1) RU2560701C2 (es)
SG (2) SG175188A1 (es)
TW (2) TW201526923A (es)
UY (1) UY32609A (es)
WO (1) WO2010129469A1 (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
RO123028B1 (ro) * 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2500037A3 (en) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
CN101454025B (zh) 2006-04-05 2014-01-01 艾伯维生物技术有限公司 抗体纯化
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
NZ572765A (en) 2006-06-30 2012-08-31 Abbott Biotech Ltd Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
RU2486296C2 (ru) * 2006-10-27 2013-06-27 Эбботт Байотекнолоджи Лтд. КРИСТАЛЛИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFα
EP2142565A4 (en) * 2007-03-29 2010-03-31 Abbott Lab CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
US8753839B2 (en) 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
MX2010007393A (es) * 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
US8758301B2 (en) 2009-12-15 2014-06-24 Abbvie Biotechnology Ltd Firing button for automatic injection device
EP2531613A2 (en) 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
WO2011153477A2 (en) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Uses and compositions for treatment of hidradenitis suppurativa (hs)
JP5919606B2 (ja) * 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
US9265887B2 (en) 2011-01-24 2016-02-23 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2012111762A1 (ja) * 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
BR112015009462A2 (pt) * 2012-10-26 2017-07-04 Lupin Atlantis Holdings Sa composição farmacêutica estável do tnfr:fc proteína de fusão
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CN102988984B (zh) * 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
CA2898262A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
CN103446583B (zh) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 一种治疗TNF-α相关疾病的人抗体制剂
JP2014202667A (ja) * 2013-04-08 2014-10-27 株式会社島津製作所 抗体医薬用粒子径分布測定装置及び抗体医薬の粒子径分布測定方法
EP3003369A4 (en) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
MX2016000405A (es) * 2013-07-19 2016-09-09 Hexal Ag Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
WO2015038777A1 (en) * 2013-09-11 2015-03-19 Arsia Therapeutics, Inc. Liquid protein formulations containing water soluble organic dyes
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
DK3060229T3 (da) * 2013-10-24 2021-10-11 Astrazeneca Ab Stabile, vandige antistofformuleringer
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
KR101712245B1 (ko) * 2013-11-29 2017-03-06 아레스 트레이딩 에스.에이. TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US10918698B2 (en) * 2014-03-29 2021-02-16 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of Fc-peptide fusion protein
HUE029849T2 (en) * 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) * 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
JP6894239B2 (ja) * 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
WO2015190378A1 (ja) * 2014-06-10 2015-12-17 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定なアダリムマブ水性製剤
AR102198A1 (es) * 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201636047A (zh) * 2015-01-28 2016-10-16 麥博賽恩斯有限公司 抗－ＴＮＦ－α抗體之醫藥調配物
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
EP4338752A3 (en) * 2016-06-30 2024-04-03 Celltrion, Inc. Stable liquid pharmaceutical preparation
MY196321A (en) 2016-08-16 2023-03-24 Regeneron Pharma Methods for Quantitating Individual Antibodies From a Mixture
AU2017350807B2 (en) 2016-10-25 2022-07-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN107485713B (zh) * 2017-07-31 2018-08-28 百奥泰生物科技(广州)有限公司 针对TNF-α的抗体组合物及其应用
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2019057631A1 (en) 2017-09-20 2019-03-28 Alvotech Hf PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB
BR112020006321A2 (pt) 2017-09-30 2020-11-17 Biocells (Beijing) Biotech Co., Ltd. composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória
EA201900360A1 (ru) * 2017-12-29 2019-12-30 Закрытое Акционерное Общество "Биокад" ВОДНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА К ФНОα
MX2020009935A (es) * 2018-03-23 2021-01-08 Abbvie Deutschland Formulaciones acuosas y estables de anticuerpos anti-tau.
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20230158143A1 (en) * 2020-05-21 2023-05-25 Shilpa Medicare Ltd Pharmaceutical compositions comprising adalimumab

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237054A (en) * 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
RO123028B1 (ro) * 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Anticorpi umani, care leagă tnf alpha uman
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
EP1174148A4 (en) * 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
WO2002011753A1 (fr) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
SE0003045D0 (sv) * 2000-08-29 2000-08-29 Probi Ab New method
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
WO2002096461A1 (en) * 2001-05-25 2002-12-05 Abbott Gmbh & Co. Kg Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
ES2338218T3 (es) * 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
AU2002359495A1 (en) * 2001-11-30 2003-06-17 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
WO2003068259A1 (en) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP3417875B1 (en) * 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
ES2349779T5 (es) * 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
HUE026793T2 (en) * 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
US20080145383A1 (en) * 2004-03-12 2008-06-19 Intercell Ag Method for Solubilizing Peptide Mixtures
US7279448B2 (en) * 2004-07-08 2007-10-09 The United States Of America, As Represented By The Secretary Of Agriculture Poly(hydroxy thioether) vegetable oil derivatives useful as lubricant additives
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7119876B2 (en) * 2004-10-18 2006-10-10 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
JP4890537B2 (ja) * 2005-04-18 2012-03-07 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 安定化抗ｂ型肝炎ウイルス（ｈｂｖ）抗体製剤
EP2500037A3 (en) * 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
ATE501248T1 (de) * 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
NZ599176A (en) * 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
WO2007037795A2 (en) * 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
TW201337266A (zh) * 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
WO2007092829A2 (en) * 2006-02-07 2007-08-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
CN101454025B (zh) * 2006-04-05 2014-01-01 艾伯维生物技术有限公司 抗体纯化
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2012586A4 (en) * 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
NZ572765A (en) * 2006-06-30 2012-08-31 Abbott Biotech Ltd Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
RU2486296C2 (ru) * 2006-10-27 2013-06-27 Эбботт Байотекнолоджи Лтд. КРИСТАЛЛИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFα
CN101631535A (zh) * 2006-12-06 2010-01-20 惠氏公司 含有甘露醇的高蛋白质浓度调配物
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101678066B (zh) * 2007-04-26 2014-09-24 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
EP2165194A4 (en) * 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
US20110014676A1 (en) * 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
US20090029794A1 (en) * 2007-07-23 2009-01-29 Yung-Hsiung Chen Golf Club Head that Reduces a Contact Resistance with the Ground
US8753839B2 (en) * 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
EP2271671A2 (en) * 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
JP5677411B2 (ja) * 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
EP2531613A2 (en) * 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor

Also Published As

Publication number Publication date
US20140141008A1 (en) 2014-05-22
CN102458469A (zh) 2012-05-16
RU2560701C2 (ru) 2015-08-20
CN104490767A (zh) 2015-04-08
TWI480064B (zh) 2015-04-11
SG10201401995UA (en) 2014-08-28
AU2010246168A1 (en) 2011-11-10
UY32609A (es) 2010-12-31
NZ595694A (en) 2013-09-27
KR20120038406A (ko) 2012-04-23
RU2011149327A (ru) 2013-06-10
SG175188A1 (en) 2011-11-28
EP2427211A1 (en) 2012-03-14
AR076748A1 (es) 2011-07-06
CN102458469B (zh) 2014-12-24
NZ613809A (en) 2015-02-27
CA2760185A1 (en) 2010-11-11
JP2012526121A (ja) 2012-10-25
TW201526923A (zh) 2015-07-16
EP2427211A4 (en) 2013-05-01
IL215643A0 (en) 2012-01-31
TW201043263A (en) 2010-12-16
US20140141007A1 (en) 2014-05-22
US20100278822A1 (en) 2010-11-04
WO2010129469A8 (en) 2012-02-23
WO2010129469A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
MX2012007794A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r).
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
NZ605874A (en) Methods and compositions for cns delivery of heparan n-sulfatase
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
NZ605871A (en) Treatment of sanfilippo syndrome type b
UA91044C2 (uk) Жива послаблена ротавірусна вакцина для перорального застосування
BR112014026718A2 (pt) variantes ctla-4
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
NZ711567A (en) Antibody formulations
WO2008076257A3 (en) Treating cancer with anti-igflr antibody 19d12 = sch 717454
MX2022009523A (es) Formulaciones farmaceuticas.
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
MX2021014332A (es) Formulaciones estabilizadas que contienen anticuerpos anti-angptl3.
HK1120417A1 (en) Stable nanoparticle formulations
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2007121471A3 (en) Dialkyl ether delivery agents
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.

FA Abandonment or withdrawal